VCYT vs. VRDN, GH, FLGT, CSTL, CELC, CDNA, BNR, PSNL, RDNT, and FTRE
Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Viridian Therapeutics (VRDN), Guardant Health (GH), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Celcuity (CELC), CareDx (CDNA), Burning Rock Biotech (BNR), Personalis (PSNL), RadNet (RDNT), and Fortrea (FTRE). These companies are all part of the "medical laboratories" industry.
Veracyte (NASDAQ:VCYT) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Veracyte has higher revenue and earnings than Viridian Therapeutics. Veracyte is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Veracyte has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
In the previous week, Viridian Therapeutics had 1 more articles in the media than Veracyte. MarketBeat recorded 4 mentions for Viridian Therapeutics and 3 mentions for Veracyte. Veracyte's average media sentiment score of 1.20 beat Viridian Therapeutics' score of 0.00 indicating that Veracyte is being referred to more favorably in the media.
Veracyte presently has a consensus target price of $29.00, indicating a potential upside of 42.51%. Viridian Therapeutics has a consensus target price of $36.60, indicating a potential upside of 137.66%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Veracyte.
Veracyte has a net margin of -20.61% compared to Viridian Therapeutics' net margin of -75,711.48%. Veracyte's return on equity of -2.02% beat Viridian Therapeutics' return on equity.
Veracyte received 384 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 73.02% of users gave Viridian Therapeutics an outperform vote while only 72.88% of users gave Veracyte an outperform vote.
Summary
Veracyte beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Veracyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Veracyte Competitors List
Related Companies and Tools
